Robot’s surgeon or surgeon’s robot? Swiss innovator Distalmotion is pressing ahead with the latter approach having added new directors, and new funding and commercial scale-up resources to further the global vision for its laparoscopic-robotic surgery tool with a difference.
Patients at the center of their care, and surgeons at the center of delivering it. That is the concept being advanced by Swiss company Distalmotion SA as it moves ahead with plans for the commercial launch of its robotic assisted, laparoscopy surgery tool.
The company, led since 2014 by CEO Michael Friedrich, has announced an important new $90m series E financing to bring to market its Dexter surgical robot and accelerate the...
TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.
The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.
Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.
